Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 02-18 13:07:42 EST

74.77

-0.09

-0.12%

High74.94	Low74.39	Vol432.45M
Open74.86	D1 Closing74.86	Amplitude0.72%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O6.32B	T/O Rate--	Tradable Shares0.00
P/B7.4028	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":74.77056,"timestamp":1771438062412,"preClose":74.86262,"halted":0,"volume":432450100,"delay":0,"changeRate":-0.00123,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.092056,"latestTime":"02-18 13:07:42 EST","open":74.863304,"high":74.93602,"low":74.39489,"amount":6316791892.916533,"amplitude":0.007228,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.4028,"peRate":-184.336219,"turnoverRate":0.012964,"increases":356,"decrements":147,"flats":13,"marketCap":1936921128109,"floatMarketCap":1737228724927},"requestUrl":"/m/hq/s/BK4139/wiki","defaultTab":"wiki","newsList":[{"id":"2612494419","title":"Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612494419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612494419?lang=en_us&edition=fundamental","pubTime":"2026-02-18 16:10","pubTimestamp":1771402224,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and RenovoRx (RNXT – R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-ag-otherrhhvf-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-ag-otherrhhvf-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","XBI","BK4210","HCSG","AG","BK4539","BK4588","BK4585","LU0029874061.USD","RNXT","XLV","LU0128526141.USD","BK4139","BK4581"],"gpt_icon":0},{"id":"2612924416","title":"U.S. RESEARCH ROUNDUP-Goosehead Insurance, Trade Desk, Watsco","url":"https://stock-news.laohu8.com/highlight/detail?id=2612924416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612924416?lang=en_us&edition=fundamental","pubTime":"2026-02-18 15:21","pubTimestamp":1771399288,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Goosehead Insurance, Trade Desk, WatscoFeb 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Goos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL8N3ZE0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU0348723411.USD","SG9999001424.SGD","LU1169590202.USD","BK4213","BK4009","BK4585","BK4588","LU1861220033.SGD","TTD","BK4532","LU1917777945.USD","LU1974910355.USD","LU2265009873.SGD","LU1804176565.USD","IE00B19Z8W00.USD","BK4528","LU2106854487.HKD","BK4613","BK4023","LU1861215975.USD","LU1989764664.SGD","BK4581","GSHD","IE00BMPRXR70.SGD","WSO","LU1923622291.USD","LU2286300806.USD","IE00BMPRXN33.USD","IE0008368304.USD","LU0266013472.USD","LU1548497426.USD","LU2023250504.SGD","LU1989764748.USD","BK4560","LU1623119135.USD","LU2210150020.SGD","LU1169589451.USD","LU2355687059.USD","BK4550","LU2357305700.SGD","LU2095319765.USD","PANW","BK4097","LU1712237335.SGD","BK4548","LU1720051108.HKD","BK4173","IE00B19Z9505.USD","CRK"],"gpt_icon":1},{"id":"2612941303","title":"Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2612941303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612941303?lang=en_us&edition=fundamental","pubTime":"2026-02-18 14:00","pubTimestamp":1771394440,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. (COGT) has disclosed a new risk, in the Innovation / R&D category. An external analyst notes that although bezuclastinib h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/analyst-warns-bezuclastinibs-fda-breakthrough-and-rtor-status-may-not-translate-into-faster-approvals-or-investor-gains?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/analyst-warns-bezuclastinibs-fda-breakthrough-and-rtor-status-may-not-translate-into-faster-approvals-or-investor-gains?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","COGT"],"gpt_icon":0},{"id":"2612413291","title":"A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2612413291","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612413291?lang=en_us&edition=fundamental","pubTime":"2026-02-18 13:28","pubTimestamp":1771392501,"startTime":"0","endTime":"0","summary":"Why Savara’s recent FDA progress is back in focus\nSavara (SVRA) is back on investor radars after resubmitting its biologics license application, completing a tech transfer to Fujifilm, and aligning key analytical protocols with the FDA.\nWith an FDA filing decision expected in the near term and management expressing strong confidence in the updated package, the upcoming Guggenheim Securities Emerging Outlook, Biotech Summit presentation on February 11 is drawing extra attention from...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-recent-fda-progress-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-recent-fda-progress-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SVRA","LU2065732104.USD","BK4139","PRGS","BK4097"],"gpt_icon":0},{"id":"2612413479","title":"Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612413479","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612413479?lang=en_us&edition=fundamental","pubTime":"2026-02-18 13:25","pubTimestamp":1771392322,"startTime":"0","endTime":"0","summary":"Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the gene editing trial to resume.\nThe decision follows updates to safety protocols after rare adverse events were evaluated.\nThe cleared pathway enables expanded enrollment for MAGNITUDE-2 and continued work on Intellia's in vivo gene editing program.\n\nFor you as an investor looking at Intellia Therapeutics (NasdaqGM:NTLA), this regulatory step comes as the stock trades at $12.22. The share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/clinical-hold-lift-on-magnitude-2-resets-risk-reward-for-int","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/clinical-hold-lift-on-magnitude-2-resets-risk-reward-for-int","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","ISBC","BK4535","NTLA","BK4139","BK4211","BK4556","BK4588","BK4585"],"gpt_icon":0},{"id":"2612975274","title":"HCW Biologics Prices $1.5 Million Offering With Warrants at $0.6055 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2612975274","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612975274?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:51","pubTimestamp":1771383066,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. has announced the pricing of a follow-on offering consisting of 2,477,292 units, each including one share of common stock  and one warrant to purchase one share of common stock at an exercise price of $0.6055 per share. The warrants will become exercisable upon shareholder approval and expire five years after that date. The company also reached an agreement to reduce the exercise price of certain existing warrants from $2.41 to $0.6055 per share, subject to shareholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL76Y2t0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4539","LU0314104364.USD","BK4112","BK4588","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","HCWB","SG9999014021.USD","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2612497542","title":"HCW Biologics Announces Pricing of $1.5 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2612497542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612497542?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:50","pubTimestamp":1771383059,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA87H3CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","HCWB"],"gpt_icon":0},{"id":"2612497522","title":"Press Release: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2612497522","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612497522?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:50","pubTimestamp":1771383000,"startTime":"0","endTime":"0","summary":"MIRAMAR, Fla., Feb. 17, 2026  -- HCW Biologics Inc. , , a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock  and one warrant, each to purchase one share of common stock. The warrant will have an exercise price of $0.6055 per share, will be exercisable upon shareholder approval, and will expire on the five-year anniversary from such date of shareholder approval. The shares of common stock  and the warrant comprising the units are immediately separable and will be issued separately in this offering. The closing of the offering is expected to occur on or about February 19, 2026, subject to the satisfaction of customary closi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","SQQQ","USAW.SI","BK4099","PSQ","QID","TSYW.SI","BK4139",".IXIC","BK4588","QYLD","TM","QQQJ","HCWB","BK4585","QYLG","JEPQ","BK4555","QQQY","NQmain","03160","BK4539","QQQE","MNQmain","QLD","BK4604","GPIQ","USJW.SI","NVIW.SI"],"gpt_icon":1},{"id":"2612973624","title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612973624","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612973624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:40","pubTimestamp":1771382418,"startTime":"0","endTime":"0","summary":"Adam S. Grossman, President and CEO of ADMA Biologics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6ZlynS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2612449204","title":"Olema Pharmaceuticals Files Initial Beneficial Ownership Statement for Sasha Lu, VP of Finance and Controller","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449204","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449204?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:33","pubTimestamp":1771382034,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals Inc. has filed an initial statement of beneficial ownership for Sasha Lu, who serves as VP of Finance and Controller. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL4n8CPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Olema Pharmaceuticals Files Initial Beneficial Ownership Statement for Sasha Lu, VP of Finance and Controller","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","OLMA"],"gpt_icon":0},{"id":"2612924134","title":"Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612924134","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612924134?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:16","pubTimestamp":1771380970,"startTime":"0","endTime":"0","summary":"Pamela Stephenson, Chief Commercial Officer, reported a disposal of common shares of Disc Medicine Inc. i. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8Lt3mD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","IRON","BK4139"],"gpt_icon":0},{"id":"2612924484","title":"10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612924484","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612924484?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:15","pubTimestamp":1771380913,"startTime":"0","endTime":"0","summary":"Charles Cherington, a 10% owner, reported the acquisition of common shares of Ernexa Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2YFxhK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"gpt_icon":0},{"id":"2612049260","title":"Disc Medicine CEO John D. Quisel Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612049260","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612049260?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:04","pubTimestamp":1771380264,"startTime":"0","endTime":"0","summary":"John D. Quisel, Chief Executive Officer and Director, reported a disposal of common shares of Disc Medicine Inc. i. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL66ztMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Disc Medicine CEO John D. Quisel Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","IRON"],"gpt_icon":0},{"id":"2612921284","title":"PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2612921284","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612921284?lang=en_us&edition=fundamental","pubTime":"2026-02-18 09:21","pubTimestamp":1771377673,"startTime":"0","endTime":"0","summary":"PTC Therapeutics, Inc. (NasdaqGS:PTCT) has withdrawn its planned resubmission of the New Drug Application for Translarna following feedback from the US Food and Drug Administration.\nThe decision affects Translarna's potential US path for treating patients with Duchenne muscular dystrophy caused by nonsense mutations.\nThe update centers on regulatory communication, not on new clinical data releases.\n\nPTC Therapeutics focuses on therapies for rare diseases, so each regulatory decision can...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/ptc-therapeutics-faces-translarna-setback-while-valuation-si","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/ptc-therapeutics-faces-translarna-setback-while-valuation-si","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","PTC","PTCT","SG9999014005.SGD","SG9999014021.USD","LU1721428347.USD","LU0109394709.USD","BK4576","BK4023","LU2506952410.USD","LU0889565916.HKD","LU2506952337.HKD","BK4585","LU2362541513.USD","BK4139","LU1951200564.SGD","LU1923623000.USD","LU2362541273.HKD","LU1951198990.SGD","BK4554","LU2477742899.HKD","LU0320765992.SGD","LU2362540622.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2612549499","title":"Nicole Murphy, Head of Pharm Ops and Tech, acquires Biogen Inc. common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612549499","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612549499?lang=en_us&edition=fundamental","pubTime":"2026-02-18 09:17","pubTimestamp":1771377446,"startTime":"0","endTime":"0","summary":"Nicole Murphy, Head of Pharm Ops and Tech, reported the acquisition of common shares of Biogen Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL1JZxMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nicole Murphy, Head of Pharm Ops and Tech, acquires Biogen Inc. common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4588","BK4139","BK4532","LU0320765992.SGD","IE00B894F039.SGD","BK4585","BIIB","LU0109394709.USD","BK4533","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2612949684","title":"Director Srinivas Akkaraju Reports Acquisition of Kalaris Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612949684","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612949684?lang=en_us&edition=fundamental","pubTime":"2026-02-18 09:16","pubTimestamp":1771377379,"startTime":"0","endTime":"0","summary":"Srinivas Akkaraju, Director and 10% Owner, reported the acquisition of common shares of Kalaris Therapeutics Inc., along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6vgWlV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Srinivas Akkaraju Reports Acquisition of Kalaris Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2612491940","title":"Alnylam CFO Jeffrey V. Poulton Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612491940","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612491940?lang=en_us&edition=fundamental","pubTime":"2026-02-18 08:26","pubTimestamp":1771374398,"startTime":"0","endTime":"0","summary":"Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL3f76Mm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alnylam CFO Jeffrey V. Poulton Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0320765992.SGD","LU0882574055.USD","LU0114720955.EUR","LU0889565916.HKD","BK4588","LU0109394709.USD","BK4139","BK4548","ALNY"],"gpt_icon":0},{"id":"2612990214","title":"Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612990214","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612990214?lang=en_us&edition=fundamental","pubTime":"2026-02-18 08:01","pubTimestamp":1771372867,"startTime":"0","endTime":"0","summary":"Feb 17 (Reuters) - Halozyme Therapeutics Outlook FY revenue USD 1,385-1,400 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 17-FEB-202623:40:00.027 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nRSD9z8wv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2612499799","title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2612499799","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612499799?lang=en_us&edition=fundamental","pubTime":"2026-02-18 07:57","pubTimestamp":1771372629,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL4CZk0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2612478493","title":"Synopsys Jumps over 2% While APLD Plunges 9%. Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD","url":"https://stock-news.laohu8.com/highlight/detail?id=2612478493","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612478493?lang=en_us&edition=fundamental","pubTime":"2026-02-18 07:38","pubTimestamp":1771371481,"startTime":"0","endTime":"0","summary":"Synopsys jumped about 2.5% in extended trading. Applied Digital plunged over 9%, WeRide dank over 2%, Recursion Pharmaceuticals fell over 1%.Nvidia reports share stake of 4.8 million shares in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nRSD2s9703:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004091025.USD","LU1037948541.HKD","HK0000320264.USD","LU2756315664.SGD","LU2931357623.SGD","LU2505996509.AUD","LU1914381329.SGD","LU1983260115.SGD","SG9999014906.USD","LU1868836591.USD","IE00BKVL7J92.USD","LU2111349929.HKD","IE00BFSS8Q28.SGD","LU0029864427.USD","LU1119994496.HKD","IE00B3S45H60.SGD","IE00BFSS7M15.SGD","SG9999000418.SGD","IE0005OL40V9.USD","LU0128525929.USD","LU2125909247.SGD","LU0640476718.USD","BK4585","LU1814569148.SGD","LU0708994859.HKD","LU1974910355.USD","HK0000306701.USD","LU2360032135.SGD","LU1303367103.USD","LU0965509283.SGD","LU1037948897.HKD","IE00BKDWB100.SGD","LU0965509101.SGD","LU0289960550.SGD","LU2322448791.USD","SG9999015978.USD","IE0003U64NQ7.SGD","LU0256863811.USD","BK4548","LU1720051108.HKD","LU2125909916.SGD","LU2237438978.USD","IE00BZ199S13.USD","LU0210533765.USD","SG9999015358.SGD","LU2896262040.SGD","LU0170899867.USD","LU0077335932.USD","LU0823414551.USD","LU1623119135.USD","LU1642822529.SGD","LU2602419157.SGD","LU2458330243.SGD","LU1699723380.USD","SG9999014914.USD","LU2087621335.USD","LU2473716301.USD","LU0053666078.USD","LU0251132253.USD","LU0289739343.SGD","LU1935042991.SGD","LU0476273544.USD","LU2430703251.USD","LU2211815571.USD","LU0011850046.USD","LU1861214812.USD","NOK","IE0009G5SDU7.USD","LU1153585028.USD","LU0820561909.HKD","LU0823414478.USD","SG9999015945.SGD","LU2065171311.SGD","LU0238689110.USD","IE00BMPRXR70.SGD","BK4567","LU0274383776.USD","LU1429558221.USD","LU2272731865.HKD","BK4141","LU1066051498.USD","IE00BKPKM429.USD","BK4612","LU2361044949.HKD","SG9999001424.SGD","IE00B19Z8W00.USD","LU1992135472.HKD","BK4543","LU1861219969.SGD","LU1084165304.USD","LU1244550221.USD","LU0124676726.USD","LU0234572021.USD","LU2505996681.GBP","LU0820562030.AUD","LU1629891620.HKD","LU2463028550.USD","IE0004445239.USD","IE00B3M56506.USD","LU2168564222.USD","LU0353189680.USD","LU0354030511.USD","LU1242518857.USD","LU2290526834.HKD","LU1721428933.USD","IE00B1BXHZ80.USD","IE000W1ABFV2.USD","LU1244550494.USD","BK4551","LU2360106780.USD","BK4592","LU1989772923.USD","LU2456880835.USD","LU2746668461.USD","BK1531","LU2244417387.USD","LU1571399168.USD","LU1496350502.SGD","LU0557290698.USD","LU1854103824.USD","LU2077746001.SGD","LU2089985449.USD","LU1232071149.USD","SG9999015986.USD","LU1923622291.USD","LU0158827948.USD","LU0787776722.HKD","LU0724617625.USD","SG9999018857.SGD","SG9999014542.SGD","BK4581","IE00BDCRKT87.USD","LU0267386448.USD","LU0861579265.USD","LU1548497426.USD","LU0494093205.USD","LU1868836914.USD","LU1992135399.USD","IE00B4JS1V06.HKD","LU2355687059.USD","BK4124","LU2271345857.HKD","LU2750360641.GBP","LU0006306889.USD","LU2242650005.HKD","IE00BD6J9T35.USD","LU0265550946.USD","INTC","IE00BQXX3D17.EUR","LU0107464264.USD","LU0109391861.USD","LU2491050154.USD","HK0000914660.USD","IE0004086264.USD","BK4023","LU2098885051.SGD","ARM","LU2506951792.HKD","IE00B1XK9C88.USD","LU2750360997.AUD","LU2168563687.JPY","LU1435385759.SGD","LU1934455277.USD","LU1989764664.SGD","LU2265009873.SGD","LU2089284900.SGD","LU2360107325.USD","BK4614","LU1261432733.SGD","BK4575","LU0957808578.USD","LU0345769631.USD","LU0719512351.SGD","LU0820561818.USD","LU2471134523.USD","LU2462157665.USD","LU0203202063.USD","LU1803068979.SGD","BK4579","LU1066051225.USD","LU2108987350.USD","LU0096362180.USD","SGXZ99366536.SGD","LU1718418525.SGD","LU1989764748.USD","LU0320765059.SGD","SG9999014575.USD","LU1127390331.HKD","LU0061474960.USD","LU2286300806.USD","LU0868494617.USD","LU2420271590.USD","IE00BYXW3230.USD","SG9999014559.SGD","LU2065171402.SGD","LU1951200564.SGD","IE00BJTD4V19.USD","BK4512","IE0004445015.USD","LU0234570918.USD","LU0642271901.SGD","LU2746668974.SGD","LU0348723411.USD","IE00BK4W5L77.USD","LU0788109477.HKD","LU1280957306.USD","LU2092937148.SGD","LU2430703178.SGD","IE00BJTD4N35.SGD","SG9999002224.SGD","LU2065170008.USD","LU2322448957.HKD","LU0266013472.USD","LU1988902786.USD","LU1854104046.USD","LU2357125470.USD","IE00BWXC8680.SGD","LU2452424414.USD","LU2592432038.USD","LU1839511570.USD","LU0210528500.USD","LU0308772762.SGD","LU2023251221.USD","LU2413666426.HKD","LU1066053197.SGD","LU0079474960.USD","LU0528227936.USD","LU2168564065.EUR","LU2756315318.SGD","LU0511384066.AUD","LU2552382058.USD","LU1821325948.USD","LU2357305700.SGD","LU0048584097.USD","LU2092627202.USD","LU0225283273.USD","LU1815336760.USD","BK4515","LU2272731782.SGD","GB00BDT5M118.USD","SGXZ51526630.SGD","LU2211814178.USD","IE000YTNTUN2.SGD","LU0823421416.USD","SG9999014898.SGD","IE000ITXATA3.USD","BK4602","LU1551013342.USD","LU0157215616.USD","LU2213496289.HKD","BK4608","LU2168564495.EUR","IE00BN29S564.USD","LU0289961442.SGD","LU0265550359.USD","LU2458330169.SGD","LU0080751232.USD","LU2247934214.USD","LU2083900584.USD","LU0321505868.SGD","LU2249611893.SGD","LU1496350171.SGD","LU2125909593.SGD","IE00BHPRN162.USD","LU0187121727.USD","LU0965508806.USD","LU2264538146.SGD","IE00BJJMRX11.SGD","IE00B7KXQ091.USD","RXRX","LU2430703095.HKD","LU0061475181.USD","LU1366192091.USD","LU1804176565.USD","LU0175139822.USD","LU1145028129.USD","LU0154236417.USD","IE0034235303.USD","SG9999002232.USD","LU1791710582.SGD","IE00B19Z9505.USD","LU0256863902.USD","IE0034235295.USD","LU1861220033.SGD","LU1868837300.USD","IE00BZ1G4Q59.USD","LU0985320562.USD","LU1116320737.USD","LU0347712357.USD","LU0061474705.USD","LU1935043023.USD","LU0198837287.USD","LU0889565833.HKD","LU0106261372.USD","SG9999018865.SGD","IE0034235188.USD","LU1064131342.USD","LU0082616367.USD","LU1778281490.HKD","LU1935042488.USD","LU0823421333.USD","LU0444973449.USD","HK0000914686.HKD","LU0211327993.USD","LU2168564149.EUR","LU0868494708.USD","BK4533","LU1674673691.USD","IE00B3SWFQ91.USD","LU0823434740.USD","LU2471134952.CNY","LU2417539215.USD","LU0215105999.USD","IE00B19Z8X17.USD","LU0444971666.USD","LU1934455863.HKD","BK4605","BK4532","LU0127658192.USD","IE00BJLML261.HKD","LU1852331112.SGD","LU2381873111.SGD","LU0689626769.HKD","LU0094547139.USD","LU1066051811.HKD","LU0069063385.USD","LU2242649171.HKD","IE00BJJMRY28.SGD","LU0310800379.SGD","LU0964807845.USD","LU2433249047.HKD","LU2361045086.USD","LU1551013425.SGD","LU0210536198.USD","LU2087625088.SGD","LU2552382132.HKD","BK1229","LU0158827781.USD","SG9999017495.SGD","IE000KEQY171.SGD","IE00B5949003.HKD","LU1935042215.USD","IE00BQXX3F31.USD","LU2294711713.HKD","LU0683600562.USD","IE00BK4W5M84.HKD","BK4534","BK4539","LU2413666699.HKD","LU0070217475.USD","LU0672654240.SGD","LU2028103732.USD","LU1267930573.SGD","LU2543165471.USD","LU1868837136.USD","SGXZ23171101.USD","LU1791710400.SGD","LU2191332357.HKD","LU0081259029.USD","LU2403377893.USD","IE00B775H168.HKD","LU2063271972.USD","BK4527","LU2125154935.USD","BK4549","BK4587","LU2237957811.SGD","LU0472753341.HKD","IE00BMPRXQ63.HKD","LU0211328371.USD","LU2106854487.HKD","LU2065169927.USD","SNPS","LU0353189763.USD","LU0056508442.USD","LU2237957902.USD","LU2491049909.HKD","LU0417517546.SGD","LU1242518931.SGD","BK1104","LU0354030438.USD","LU0466842654.USD","LU0310799852.SGD","LU2148611432.USD","LU2326559502.SGD","LU1712237335.SGD","LU0345770308.USD","LU1934455194.USD","SG9999015952.SGD","LU1244550577.SGD","LU2487616109.SGD","LU0109392836.USD","LU0203201768.USD","SG9999004303.SGD","LU2250418816.HKD","LU2089283258.USD","LU1267930490.SGD","LU0689472784.USD","LU0882574139.USD","SGXZ81514606.USD","IE0001KFT4U8.USD","LU2272731600.USD","LU2552382215.SGD","LU1633808545.USD","IE00B775SV38.USD","BK1144","LU1861127337.USD","IE00BMPRXN33.USD","LU0345768153.USD","IE00BQXX3C00.GBP","LU0072462426.USD","SG9999014880.SGD","BK1258","BK4554","LU1267930730.SGD","LU0942090050.USD","LU1923623000.USD","NVDA","LU1868836757.USD","LU0345770993.USD","LU2236285917.USD","BK4535","HK0000306685.HKD","LU0342679015.USD","LU0345768740.USD","LU0943347566.SGD","LU1935043536.SGD","BK4550","LU0823434583.USD","LU2491050071.SGD","LU1691799644.USD","LU1861215975.USD","LU0323591593.USD","LU1989772840.SGD","HK0000320223.HKD","LU0057025933.USD","LU1035775433.USD","LU1720051017.SGD","LU2054465674.USD","LU2023250330.USD","SGXZ31699556.SGD","LU0390134368.USD","BK4609","BK4588","IE00B4YYXB79.USD","APLD","BK4503","LU2471134879.HKD","LU0708995401.HKD","LU0276348264.USD","LU2360107168.USD","LU0979878070.USD","LU1951198990.SGD","LU1323610961.USD","IE00BDRTCR15.USD","BK4139","SG9999015341.SGD","IE0009356076.USD","LU0096364046.USD","BK4529","LU1116320901.HKD","LU2023250504.SGD","LU2361044865.SGD","LU1069344957.HKD","LU1923622614.USD","BK4611","LU2860962120.EUR","LU1674673428.USD","LU0786609619.USD","LU2097344357.USD","LU0316494557.USD","LU0321505439.SGD","BK4598","LU2125909759.SGD","LU0957791311.USD","LU2125154778.USD","LU0965509010.AUD","LU1917777945.USD","LU1316542783.SGD","LU2097344431.USD","LU0345769128.USD","SG9999014567.USD","LU0097036916.USD","LU2471134796.USD","LU2461242641.AUD","LU1366333091.USD","LU1815333072.USD"],"gpt_icon":1}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction